Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-05-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于回复《关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函》的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding their response to an inquiry letter from the Shanghai Stock Exchange about their application for a private placement of shares. It references regulatory review processes and the need for approval from the China Securities Regulatory Commission before implementation. The document is short (815 characters) and primarily serves as a disclosure of the company's reply to a regulatory inquiry and status update on the share issuance application. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. It is an announcement related to capital raising activities but does not provide substantive financial data or results. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-05-14 Chinese
神州细胞前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is titled as a report on the usage of previously raised funds by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the amount of funds raised, their allocation, actual usage, and cash management of idle funds. It references official approvals from the China Securities Regulatory Commission and includes verification reports from PwC. The document includes detailed financial figures and tables about the fundraising and usage, as well as explanations about project changes and investment returns. This matches the characteristics of a Capital/Financing Update, specifically a report on the use of proceeds from a prior fundraising event. It is not an announcement of a report publication, nor a full annual or interim report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5215 characters) supports it being a substantive report rather than a brief announcement.
2021-05-11 Chinese
神州细胞第一届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the Supervisory Board of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It discusses the review and approval of reports related to the use of previously raised funds and the internal control effectiveness certification related to financial reports as of March 31, 2021. The document includes voting results and references audit reports by PwC. The document length is short (1283 characters) and it primarily announces the meeting decisions and approvals rather than containing the full reports themselves. Therefore, it is not the full audit report or financial report but an announcement of supervisory board resolutions and approvals related to audit and internal control matters. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement of meeting resolutions and approvals, not the full audit report or financial statements themselves.
2021-05-11 Chinese
神州细胞独立董事关于公司第一届董事会第十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's first board of directors' 18th meeting. It includes independent opinions on the use of previously raised funds and the internal control effectiveness certification related to the financial report dated March 31, 2021. The document references internal control evaluation and compliance with regulatory requirements but does not contain actual financial statements or detailed financial data. It is a formal opinion related to board meeting matters rather than a full audit report or annual/interim report. The document length is short (1002 characters), and it is not a report publication announcement but a formal board-related opinion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent director opinions on board meeting issues.
2021-05-11 Chinese
北京神州细胞生物技术集团股份公司截至2021年3月31日止前次募集资金使用情况报告及鉴证报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "前次募集资金使用情况报告及鉴证报告" which translates to "Report on the Use of Previous Fundraising and Verification Report." It contains detailed audited information about the use of funds raised in a previous capital raising event, including amounts raised, usage, cash management, and investment projects. The report is issued by an accounting firm (PwC) and includes an audit opinion on the use of the funds. The document is about the usage of capital raised and the verification of that usage, which aligns with a Capital/Financing Update (CAP) filing type. It is not a full annual or interim report, nor is it a simple announcement or certification. The length and detail confirm it is a substantive report on fundraising usage and verification.
2021-05-11 Chinese
神州细胞第一届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at a board meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the meeting date, attendance, and the approval of reports related to the use of previously raised funds and internal control effectiveness as of March 31, 2021. The document does not contain the full reports themselves but rather announces the board's approval of these reports and references their availability on the Shanghai Stock Exchange website. The document length is short (1273 characters), and it serves as a meeting resolution announcement rather than a full financial or audit report. Therefore, it fits best under Board/Management Information (MANG), as it concerns board meeting decisions and approvals related to company management and governance matters.
2021-05-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.